GABRIELLOPEZGABRIEL LOPEZ8612LOPEZ, GABRIELProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25476932Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma LNature communicationsmiR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014 Dec 05; 5:5671.Nat Commun2014-12-05T00:00:002014miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.25490449Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, B?rresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GBCancer cellCopy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014 Dec 08; 26(6):863-879.Cancer Cell2014-12-08T00:00:002014Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.1881 East RoadHouston77054-3005TXAuthorship 1633481Authorship 1636157Authorship 1636164Authorship 1637105Authorship 1638233Authorship 1638594Authorship 1640291Authorship 1641842Authorship 1643082Authorship 1643511Authorship 1645535Authorship 1647562Authorship 1650844Authorship 1651434Authorship 1654382Authorship 1654973Authorship 1654983Authorship 1656103Authorship 165704Authorship 1660702Authorship 1662102Authorship 1670287Authorship 1679854Authorship 1685604Authorship 1686041Authorship 1687558Authorship 1708483Authorship 1722022Authorship 1724046Authorship 1740731Authorship 1759058Authorship 1761522Authorship 1773833Authorship 1784888Authorship 1787024Authorship 1787948Authorship 1788812Authorship 1793757Authorship 17953811Authorship 1797018Authorship 18047413Authorship 1811549Authorship 1812382Authorship 1813737Authorship 1816372Authorship 1816573Authorship 18168499Authorship 18186211Authorship 1825563Authorship 1838403Authorship 1846824Authorship 1850209Authorship 18504519Authorship 1855894Authorship 1877814Authorship 1879177Authorship 1881242Authorship 1887417Authorship 18894114Authorship 19141413Authorship 19222112Authorship 1926234Authorship 1930176Authorship 19349814Authorship 1937687Authorship 1939217Authorship 195044321748844Tucker SD, Sivaramakrishnan MR, Klostergaard J, Lopez-Berestein GJournal of leukocyte biologyIndependence of the pattern of early cytokine release from autoregulation by nitric oxide. J Leukoc Biol. 1991 Nov; 50(5):509-16.J Leukoc Biol1991-11-01T00:00:001991Independence of the pattern of early cytokine release from autoregulation by nitric oxide.2003714Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson CAnnals of internal medicineCardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med. 1991 Apr 15; 114(8):664-6.Ann Intern Med1991-04-15T00:00:001991Cardiopulmonary toxicity after liposomal amphotericin B infusion.2327772Wasan KM, Vadiei K, Lopez-Berestein G, Verani RR, Luke DRAntimicrobial agents and chemotherapyPentoxifylline in amphotericin B toxicity rat model. Antimicrob Agents Chemother. 1990 Feb; 34(2):241-4.Antimicrob Agents Chemother1990-02-01T00:00:001990Pentoxifylline in amphotericin B toxicity rat model.2449867Hopfer RL, Mehta R, Lopez-Berestein GAntimicrobial agents and chemotherapySynergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF. Antimicrob Agents Chemother. 1987 Dec; 31(12):1978-81.Antimicrob Agents Chemother1987-12-01T00:00:001987Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.2472114Pontani DR, Sun D, Brown JW, Shahied SI, Plescia OJ, Schaffner CP, Lopez-Berestein G, Sarin PSAntiviral researchInhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res. 1989 Apr; 11(3):119-25.Antiviral Res1989-04-01T00:00:001989Inhibition of HIV replication by liposomal encapsulated amphotericin B.2479067Mehta RT, Hopfer RL, Juliano RL, Lopez-Berestein GSelective cancer therapeuticsA comparison of in vitro toxicity and antifungal efficacy of membrane-active drugs after liposome encapsulation. Sel Cancer Ther. 1989; 5(3):113-7.Sel Cancer Ther1989-01-01T00:00:001989A comparison of in vitro toxicity and antifungal efficacy of membrane-active drugs after liposome encapsulation.3079667Klostergaard J, Turpin J, Lopez-Berestein GCancer researchEffector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: parameters of induction of cytotoxins from peripheral blood monocytes isolated by counterflow elutriation. Cancer Res. 1986 Feb; 46(2):662-9.Cancer Res1986-02-01T00:00:001986Effector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: parameters of induction of cytotoxins from peripheral blood monocytes isolated by counterflow elutriation.3081250Sone S, Lopez-Berestein G, Fidler IJCancer immunology, immunotherapy : CIIPotentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol Immunother. 1986; 21(2):93-9.Cancer Immunol Immunother1986-01-01T00:00:001986Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.3084656Turpin J, Hersh EM, Lopez-Berestein GJournal of immunology (Baltimore, Md. : 1950)Characterization of small and large human peripheral blood monocytes: effects of in vitro maturation on hydrogen peroxide release and on the response to macrophage activators. J Immunol. 1986 Jun 01; 136(11):4194-8.J Immunol1986-06-01T00:00:001986Characterization of small and large human peripheral blood monocytes: effects of in vitro maturation on hydrogen peroxide release and on the response to macrophage activators.3439798Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein GAntimicrobial agents and chemotherapyFormulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 1987 Dec; 31(12):1897-900.Antimicrob Agents Chemother1987-12-01T00:00:001987Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.3700295Nishioka K, Hopfer RL, el-Hagin T, Lopez-Berestein GThe Journal of antimicrobial chemotherapyProphylaxis of Candida albicans infection with tuftsin. J Antimicrob Chemother. 1986 Mar; 17(3):361-3.J Antimicrob Chemother1986-03-01T00:00:001986Prophylaxis of Candida albicans infection with tuftsin.3806172Lopez-Berestein G, Bodey GP, Frankel LS, Mehta KJournal of clinical oncology : official journal of the American Society of Clinical OncologyTreatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb; 5(2):310-7.J Clin Oncol1987-02-01T00:00:001987Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.6667410Lopez-Berestein G, Cabanillas F, Osborne BM, Libshitz HI, Bodey GPCancer investigationStudy of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders. Cancer Invest. 1983; 1(4):293-9.Cancer Invest1983-01-01T00:00:001983Study of the natural history of immunoblastic lymphadenopathy and atypical immunoproliferative disorders.7812014Smetsers TF, Mensink EJBloodSpecificity of BCR-ABL antisense oligonucleotides. Blood. 1995 Jan 15; 85(2):597-8.Blood1995-01-15T00:00:001995Specificity of BCR-ABL antisense oligonucleotides.8025286Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein GBloodLiposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood. 1994 Jul 15; 84(2):601-7.Blood1994-07-15T00:00:001994Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia.8065160Mehta K, Sadeghi T, McQueen T, Lopez-Berestein GLeukemia researchLiposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res. 1994 Aug; 18(8):587-96.Leuk Res1994-08-01T00:00:001994Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid.8118164Wasan KM, Lopez-Berestein GArchives of medical researchThe influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res. 1993; 24(4):395-401.Arch Med Res1993-01-01T00:00:001993The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers.9063678Wasan KM, Lopez-Berestein GEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical MicrobiologyDiversity of lipid-based polyene formulations and their behavior in biological systems. Eur J Clin Microbiol Infect Dis. 1997 Jan; 16(1):81-92.Eur J Clin Microbiol Infect Dis1997-01-01T00:00:001997Diversity of lipid-based polyene formulations and their behavior in biological systems.9135737Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, Hung MCGene therapySafety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Ther. 1997 Mar; 4(3):238-43.Gene Ther1997-03-01T00:00:001997Safety studies of the intraperitoneal injection of E1A--liposome complex in mice.9419967Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJOncogeneBcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 1997 Dec 04; 15(23):2767-72.Oncogene1997-12-04T00:00:001997Bcl-2 inhibits p53 nuclear import following DNA damage.10845930Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, L?pez-Berestein G, Andreeff MBloodLiposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000 Jun 15; 95(12):3929-38.Blood2000-06-15T00:00:002000Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.11450894Tari AM, Mehta A, Lopez-Berestein GJournal of chemotherapy (Florence, Italy)Modulation of Akt activity by doxorubicin in breast cancer cells. J Chemother. 2001 Jun; 13(3):334-6.J Chemother2001-06-01T00:00:002001Modulation of Akt activity by doxorubicin in breast cancer cells.12148903Ozpolat B, Lopez-Berestein GLeukemia & lymphomaLiposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia. Leuk Lymphoma. 2002 May; 43(5):933-41.Leuk Lymphoma2002-05-01T00:00:002002Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia.12644474Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein GThe Journal of biological chemistryPar-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem. 2003 May 30; 278(22):19995-20005.J Biol Chem2003-03-17T00:00:002003Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter.15172168Siwak DR, Tari AM, Lopez-Berestein GMethods in enzymologyLiposomal antisense oligonucleotides for cancer therapy. Methods Enzymol. 2004; 387:241-53.Methods Enzymol2004-01-01T00:00:002004Liposomal antisense oligonucleotides for cancer therapy.15291358Ozpolat B, Tari AM, Mehta K, Lopez-Berestein GLeukemia & lymphomaNuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma. 2004 May; 45(5):979-85.Leuk Lymphoma2004-05-01T00:00:002004Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells.15659618Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian HBloodPotential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005 Feb 01; 105(3):1366-7.Blood2005-02-01T00:00:002005Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.16061675Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AKCancer researchTherapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005 Aug 01; 65(15):6910-8.Cancer Res2005-08-01T00:00:002005Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.16914580Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchFocal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.Clin Cancer Res2006-08-15T00:00:002006Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.17716980Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AKThe Journal of biological chemistryStress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007 Oct 12; 282(41):29919-26.J Biol Chem2007-08-23T00:00:002007Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism.18424910Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat BAutophagySilencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008 Jul; 4(5):669-79.Autophagy2008-04-10T00:00:002008Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells.18519692Yang L, Hamilton SR, Sood A, Kuwai T, Ellis L, Sanguino A, Lopez-Berestein G, Boyd DDCancer researchThe previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res. 2008 Jun 01; 68(11):4321-30.Cancer Res2008-06-01T00:00:002008The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression.19088029Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CDClinical cancer research : an official journal of the American Association for Cancer ResearchNuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008 Dec 15; 14(24):8143-51.Clin Cancer Res2008-12-15T00:00:002008Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.19395869Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AKCancer biology & therapyDual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.Cancer Biol Ther2009-06-24T00:00:002009Dual targeting of EphA2 and FAK in ovarian carcinoma.20224296Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat BAutophagyTargeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010 Apr; 6(3):322-9.Autophagy2010-04-26T00:00:002010Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.21720463Khakoo AY, Liu PP, Force T, Lopez-Berestein G, Jones LW, Schneider J, Hill JTexas Heart Institute journalCardiotoxicity due to cancer therapy. Tex Heart Inst J. 2011; 38(3):253-6.Tex Heart Inst J2011-01-01T00:00:002011Cardiotoxicity due to cancer therapy.23147994Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CNClinical cancer research : an official journal of the American Association for Cancer ResearchEndoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res. 2013 Jan 01; 19(1):170-82.Clin Cancer Res2012-11-12T00:00:002012Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.24128595Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi FClinical lymphoma, myeloma & leukemiaSingle-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e47-9.Clin Lymphoma Myeloma Leuk2013-10-12T00:00:002013Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data.24379240Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen STCarcinogenesisEDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014 May; 35(5):1100-9.Carcinogenesis2013-12-30T00:00:002013EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.Cancer BiologyExperimental TherapeuticsGynecological Oncology & Reproductive MedicineLeukemiaMolecular & Cellular OncologySystems BiologyMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessor4.445380.00196371990research areas8.55910.00438982132coauthor of271.64424.248760similar to11350selected publicationsJU-SEOGLEEJU-SEOG LEE9361LEE, JU-SEOGAssociate ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorBULENTOZPOLATBULENT OZPOLAT8675OZPOLAT, BULENTAssociate ProfessorROBERTCOLEMANROBERT COLEMAN9184COLEMAN, ROBERTProfessorCRAIGLOGSDONCRAIG LOGSDON9207LOGSDON, CRAIGProfessorLINGEGOWDA SELANEREMANGALALINGEGOWDA SELANERE MANGALA9112MANGALA, LINGEGOWDA SELANEREInstructorANIL KSOODANIL K SOOD9048SOOD, ANIL KProfessorAuthorship 2121292Authorship 2122425Authorship 2123056Authorship 2123364Authorship 2124211Authorship 2124232Authorship 2124494Authorship 2124511Authorship 2125015Authorship 2128201Authorship 2128415Authorship 2129035Authorship 2129412Authorship 2130194Authorship 2130451Authorship 2131212Authorship 2131782Authorship 2132061Authorship 2132681Authorship 2133983Authorship 2134551Authorship 2135282Authorship 2135593Authorship 2136165Authorship 2136261Authorship 2136493Authorship 2139031Authorship 2141804Authorship 2145479Authorship 2146024Authorship 2146693Authorship 2148741Authorship 2149092Authorship 2154352Authorship 2156425Authorship 2161294Authorship 2163006Authorship 2164983Authorship 2165885Authorship 2175492Authorship 2178993Authorship 2187822Authorship 219110Authorship 2218264Authorship 2231196Authorship 2233883Authorship 2242841Authorship 2266056Authorship 2266414Authorship 2275538Authorship 2280214Authorship 2285447Authorship 2294188Authorship 2296701Authorship 23009011Authorship 2301787Authorship 2310743Authorship 2313359Authorship 2321894Authorship 23228312Authorship 23243815Authorship 2329676Authorship 2344447Authorship 2345434Authorship 23462719Authorship 2346734Authorship 234697101535092Walsh TJ, Lee JW, Melcher GP, Navarro E, Bacher J, Callender D, Reed KD, Wu T, Lopez-Berestein G, Pizzo PAThe Journal of infectious diseasesExperimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis. 1992 Jul; 166(1):121-33.J Infect Dis1992-07-01T00:00:001992Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis.1923909Yau JC, Brunner LJ, Lopez-Berestein G, LeMaistre CF, Luke DRPharmacotherapyTherapeutic drug monitoring of cyclosporine-lipoprotein levels. Pharmacotherapy. 1991; 11(4):291-5.Pharmacotherapy1991-01-01T00:00:001991Therapeutic drug monitoring of cyclosporine-lipoprotein levels.1940451Mehta RT, McQueen TJ, Keyhani A, Lopez-Berestein GThe Journal of infectious diseasesLiposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis. 1991 Nov; 164(5):1003-6.J Infect Dis1991-11-01T00:00:001991Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo.2132534Seong D, Sims SS, Johnson E, Swan F, Lyding J, Lopez A, Talpaz M, Kantarjian H, Emerson S, Lopez-Berestein GTransactions of the Association of American PhysiciansRegulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia. Trans Assoc Am Physicians. 1990; 103:236-41.Trans Assoc Am Physicians1990-01-01T00:00:001990Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia.2230595Turpin J, Mehta K, Blick M, Hester JP, Lopez-Berestein GJournal of leukocyte biologyEffect of retinoids on the release and gene expression of tumor necrosis factor-alpha in human peripheral blood monocytes. J Leukoc Biol. 1990 Nov; 48(5):444-50.J Leukoc Biol1990-11-01T00:00:001990Effect of retinoids on the release and gene expression of tumor necrosis factor-alpha in human peripheral blood monocytes.2355196Luke DR, Wasan KM, McQueen TJ, Lopez-Berestein GThe Journal of infectious diseasesEnhancement of the treatment of experimental candidiasis with vascular decongestants. J Infect Dis. 1990 Jul; 162(1):211-4.J Infect Dis1990-07-01T00:00:001990Enhancement of the treatment of experimental candidiasis with vascular decongestants.2364384Perez-Soler R, Lopez-Berestein G, Lautersztain J, al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar ARCancer researchPhase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res. 1990 Jul 15; 50(14):4254-9.Cancer Res1990-07-15T00:00:001990Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).2401582Vadiei K, Lopez-Berestein G, Luke DRInternational journal of obesityDisposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int J Obes. 1990 Jun; 14(6):465-72.Int J Obes1990-06-01T00:00:001990Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model.2430132Perez-Soler R, Khokhar AR, Claringbold P, Kasi LP, Lopez-Berestein GJournal of the National Cancer InstituteEffects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles. J Natl Cancer Inst. 1986 Nov; 77(5):1137-43.J Natl Cancer Inst1986-11-01T00:00:001986Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles.2987422Perez-Soler R, Lopez-Berestein G, Cabanillas F, McLaughlin P, Hersh EMJournal of clinical oncology : official journal of the American Society of Clinical OncologySuperoxide anion (O-2) production by peripheral blood monocytes in Hodgkin's disease and malignant lymphoma. J Clin Oncol. 1985 May; 3(5):641-5.J Clin Oncol1985-05-01T00:00:001985Superoxide anion (O-2) production by peripheral blood monocytes in Hodgkin's disease and malignant lymphoma.3112239Klostergaard J, Kilbourn RG, Foster WA, Lopez-Berestein GJournal of immunological methodsRapid, quantitative microassay for the monokine respiration inhibitory factor. J Immunol Methods. 1987 Jul 16; 101(1):97-108.J Immunol Methods1987-07-16T00:00:001987Rapid, quantitative microassay for the monokine respiration inhibitory factor.3214094Lopez-Berestein GAnnals of the New York Academy of SciencesLiposomes as carriers of antifungal drugs. Ann N Y Acad Sci. 1988; 544:590-7.Ann N Y Acad Sci1988-01-01T00:00:001988Liposomes as carriers of antifungal drugs.3300535Lopez-Berestein GAntimicrobial agents and chemotherapyLiposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother. 1987 May; 31(5):675-8.Antimicrob Agents Chemother1987-05-01T00:00:001987Liposomes as carriers of antimicrobial agents.3315188Perez-Soler R, Khokhar AR, Lopez-Berestein GCancer researchTreatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles. Cancer Res. 1987 Dec 15; 47(24 Pt 1):6462-6.Cancer Res1987-12-15T00:00:001987Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.3439799Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein GAntimicrobial agents and chemotherapyToxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother. 1987 Dec; 31(12):1901-3.Antimicrob Agents Chemother1987-12-01T00:00:001987Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections.3717785Lopez-Berestein GAnnals of internal medicineLiposomal amphotericin B in the treatment of fungal infections. Ann Intern Med. 1986 Jul; 105(1):130-1.Ann Intern Med1986-07-01T00:00:001986Liposomal amphotericin B in the treatment of fungal infections.3779646Perez-Soler R, Khokhar AR, Hacker MP, Lopez-Berestein GCancer researchToxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res. 1986 Dec; 46(12 Pt 1):6269-73.Cancer Res1986-12-01T00:00:001986Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles.3791565Lautersztain J, Perez-Soler R, Khokhar AR, Newman RA, Lopez-Berestein GCancer chemotherapy and pharmacologyPharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II). Cancer Chemother Pharmacol. 1986; 18(2):93-7.Cancer Chemother Pharmacol1986-01-01T00:00:001986Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).3856062Sone S, Lopez-Berestein G, Fidler IJJournal of the National Cancer InstituteKinetics and function of tumor cytotoxic factor(s) produced by human blood monocytes activated to the tumoricidal state. J Natl Cancer Inst. 1985 Mar; 74(3):583-90.J Natl Cancer Inst1985-03-01T00:00:001985Kinetics and function of tumor cytotoxic factor(s) produced by human blood monocytes activated to the tumoricidal state.3933823Saiki I, Sone S, Fogler WE, Kleinerman ES, Lopez-Berestein G, Fidler IJCancer researchSynergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res. 1985 Dec; 45(12 Pt 1):6188-93.Cancer Res1985-12-01T00:00:001985Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes.3973417Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EMThe Journal of infectious diseasesLiposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr; 151(4):704-10.J Infect Dis1985-04-01T00:00:001985Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.4052931Lopez-Berestein G, McQueen T, Mehta KCancer drug deliveryProtective effect of liposomal-amphotericin B against C. albicans infection in mice. Cancer Drug Deliv. 1985; 2(3):183-9.Cancer Drug Deliv1985-01-01T00:00:001985Protective effect of liposomal-amphotericin B against C. albicans infection in mice.4086194Perez-Soler R, Lopez-Berestein G, Jahns M, Wright K, Kasi LPInternational journal of nuclear medicine and biologyDistribution of radiolabeled multilamellar liposomes injected intralymphatically and subcutaneously. Int J Nucl Med Biol. 1985; 12(4):261-6.Int J Nucl Med Biol1985-01-01T00:00:001985Distribution of radiolabeled multilamellar liposomes injected intralymphatically and subcutaneously.6365745Mehta K, Juliano RL, Lopez-Berestein GImmunologyStimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites. Immunology. 1984 Mar; 51(3):517-27.Immunology1984-03-01T00:00:001984Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites.6372684Hopfer RL, Mills K, Mehta R, Lopez-Berestein G, Fainstein V, Juliano RLAntimicrobial agents and chemotherapyIn vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother. 1984 Mar; 25(3):387-9.Antimicrob Agents Chemother1984-03-01T00:00:001984In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.6399857Lopez-Berestein G, Rosenblum MG, Mehta RCancer drug deliveryAltered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984; 1(3):199-205.Cancer Drug Deliv1984-01-01T00:00:001984Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans.6544116Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Hersh EM, Juliano RCancer drug deliveryEffects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv. 1983; 1(1):37-42.Cancer Drug Deliv1983-01-01T00:00:001983Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis.6696909Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RLBiochimica et biophysica actaLiposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta. 1984 Mar 14; 770(2):230-4.Biochim Biophys Acta1984-03-14T00:00:001984Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.6842027Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Hersh EM, Juliano RThe Journal of infectious diseasesTreatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May; 147(5):939-45.J Infect Dis1983-05-01T00:00:001983Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.7161762Mehta K, Lopez-Berestein G, Hersh EM, Juliano RLJournal of the Reticuloendothelial SocietyUptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc. 1982 Aug; 32(2):155-64.J Reticuloendothel Soc1982-08-01T00:00:001982Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes.7759766Wasan KM, Lopez-Berestein GImmunopharmacology and immunotoxicologyThe past, present, and future uses of liposomes in treating infectious diseases. Immunopharmacol Immunotoxicol. 1995 Feb; 17(1):1-15.Immunopharmacol Immunotoxicol1995-02-01T00:00:001995The past, present, and future uses of liposomes in treating infectious diseases.7918789Wasan KM, Hayman AC, Lopez-Berestein GJournal of pharmaceutical and biomedical analysisDetermination of dimyristoylphosphatidylglycerol in human serum by liquid-liquid extraction and reversed-phase liquid chromatography. J Pharm Biomed Anal. 1994 Jun; 12(6):851-4.J Pharm Biomed Anal1994-06-01T00:00:001994Determination of dimyristoylphosphatidylglycerol in human serum by liquid-liquid extraction and reversed-phase liquid chromatography.7965656Wasan KM, Morton RE, Rosenblum MG, Lopez-Berestein GJournal of pharmaceutical sciencesDecreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci. 1994 Jul; 83(7):1006-10.J Pharm Sci1994-07-01T00:00:001994Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.8452354Wasan KM, Brazeau GA, Keyhani A, Hayman AC, Lopez-Berestein GAntimicrobial agents and chemotherapyRoles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother. 1993 Feb; 37(2):246-50.Antimicrob Agents Chemother1993-02-01T00:00:001993Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins.8611689Estey E, Thall PF, Mehta K, Rosenblum M, Brewer T, Simmons V, Cabanillas F, Kurzrock R, Lopez-Berestein GBloodAlterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood. 1996 May 01; 87(9):3650-4.Blood1996-05-01T00:00:001996Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid.8882351Vadiei K, Tucker SD, Lopez-Berestein G, Wasan KMPharmacology & toxicologyNephroprotective mechanism(s) of pentoxifylline: reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release. Pharmacol Toxicol. 1996 Mar; 78(3):174-80.Pharmacol Toxicol1996-03-01T00:00:001996Nephroprotective mechanism(s) of pentoxifylline: reduction of erythrocyte-mediated vascular congestion and inhibition of nitric oxide release.8912183Tari AM, Andreeff M, Kleine HD, Lopez-Berestein GJournal of molecular medicine (Berlin, Germany)Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J Mol Med (Berl). 1996 Oct; 74(10):623-8.J Mol Med (Berl)1996-10-01T00:00:001996Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides.9713967Tormo M, Tari AM, McDonnell TJ, Cabanillas F, Garcia-Conde J, Lopez-Berestein GLeukemia & lymphomaApoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk Lymphoma. 1998 Jul; 30(3-4):367-79.Leuk Lymphoma1998-07-01T00:00:001998Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation.10022986Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung MCOncology reportsIssues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep. 1999 Mar-Apr; 6(2):257-62.Oncol Rep1999-03-01T00:00:001999Issues in the development of gene therapy: preclinical experiments in E1A gene delivery.10456660Swaminathan N, Lopez-Berestein G, Rudikoff SMedical oncology (Northwood, London, England)Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia. Med Oncol. 1999 Jul; 16(2):119-28.Med Oncol1999-07-01T00:00:001999Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia.11350889Yoo GH, Hung MC, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JLClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001 May; 7(5):1237-45.Clin Cancer Res2001-05-01T00:00:002001Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.11890364Tari AM, Lopez-Berestein GCurrent opinion in investigational drugs (London, England : 2000)Cellular uptake of antisense oligonucleotides. Curr Opin Investig Drugs. 2001 Oct; 2(10):1450-3.Curr Opin Investig Drugs2001-10-01T00:00:002001Cellular uptake of antisense oligonucleotides.11994979Mitarnun W, Suwiwat S, Pradutkanchana J, Saechan V, Ishida T, Takao S, Mori AAmerican journal of hematologyEpstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis. Am J Hematol. 2002 May; 70(1):31-8.Am J Hematol2002-05-01T00:00:002002Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis.15721388Ng AW, Wasan KM, Lopez-Berestein GMethods in enzymologyLiposomal polyene antibiotics. Methods Enzymol. 2005; 391:304-13.Methods Enzymol2005-01-01T00:00:002005Liposomal polyene antibiotics.16514421Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, Lopez-Berestein G, Hortobagyi GN, Hung MCCancer gene therapyMutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther. 2006 Jul; 13(7):706-19.Cancer Gene Ther2006-03-03T00:00:002006Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model.16862152Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AKNature medicineChronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.Nat Med2006-07-23T00:00:002006Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.17974982Landen CN, Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AKCancer researchNeuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007 Nov 01; 67(21):10389-96.Cancer Res2007-11-01T00:00:002007Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.18491231Ozpolat B, Akar U, Zorrilla-Calancha I, Vivas-Mejia P, Acevedo-Alvarez M, Lopez-Berestein GApoptosis : an international journal on programmed cell deathDeath-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis. 2008 Jul; 13(7):915-28.Apoptosis2008-07-01T00:00:002008Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.18632639Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AKCancer researchClinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.Cancer Res2008-07-15T00:00:002008Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.19470734Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.Clin Cancer Res2009-05-26T00:00:002009Therapeutic Targeting of ATP7B in Ovarian Carcinoma.19847298Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CDPloS oneThe ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 2009 Oct 22; 4(10):e7502.PLoS One2009-10-22T00:00:002009The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment.20430760Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari MCancer researchSustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96.Cancer Res2010-05-01T00:00:002010Sustained small interfering RNA delivery by mesoporous silicon particles.20682653Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AKMolecular cancer therapeuticsConverging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.Mol Cancer Ther2010-08-03T00:00:002010Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.20889728Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AKMolecular cancer therapeuticsTargeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99.Mol Cancer Ther2010-10-01T00:00:002010Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.21421858Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RKClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011 Apr 15; 17(8):2250-9.Clin Cancer Res2011-03-18T00:00:002011Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.21627858Rupaimoole R, Han HD, Lopez-Berestein G, Sood AKChinese journal of cancerMicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011 Jun; 30(6):368-70.Chin J Cancer2011-06-01T00:00:002011MicroRNA therapeutics: principles, expectations, and challenges.21753153Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CNClinical cancer research : an official journal of the American Association for Cancer ResearchTargeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85.Clin Cancer Res2011-07-13T00:00:002011Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.22028766Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LMPloS oneNeuropilin-2 mediated ?-catenin signaling and survival in human gastro-intestinal cancer cell lines. PLoS One. 2011; 6(10):e23208.PLoS One2011-10-20T00:00:002011Neuropilin-2 mediated ?-catenin signaling and survival in human gastro-intestinal cancer cell lines.23344261Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SCClinical cancer research : an official journal of the American Association for Cancer ResearchIdentification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20.Clin Cancer Res2013-01-23T00:00:002013Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.23389994Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JSHepatology (Baltimore, Md.)Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013 Jul; 58(1):182-91.Hepatology2013-05-15T00:00:002013Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520.23410973Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang WCancer cellIntegrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99.Cancer Cell2013-02-11T00:00:002013Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.23585472Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AKThe Journal of clinical investigationATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.J Clin Invest2013-04-15T00:00:002013ATP11B mediates platinum resistance in ovarian cancer.24018975Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AKNature communicationsTumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.Nat Commun2013-01-01T00:00:002013Tumour angiogenesis regulation by the miR-200 family.24236104Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee PPloS oneCystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.PLoS One2013-11-13T00:00:002013Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.24556724Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AKCancer researchMonocyte subpopulations in angiogenesis. Cancer Res. 2014 Mar 01; 74(5):1287-93.Cancer Res2014-02-20T00:00:002014Monocyte subpopulations in angiogenesis.25026212Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AKCancer cellHematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.Cancer Cell2014-07-14T00:00:002014Hematogenous metastasis of ovarian cancer: rethinking mode of spread.25043055Krzeszinski JY, Wei W, Huynh H, Jin Z, Wang X, Chang TC, Xie XJ, He L, Mangala LS, Lopez-Berestein G, Sood AK, Mendell JT, Wan YNaturemiR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014 Aug 28; 512(7515):431-5.Nature2014-06-25T00:00:002014miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.Authorship 2361193Authorship 2361923Authorship 2361972Authorship 2362343Authorship 2363092Authorship 2363738Authorship 2364711Authorship 2366453Authorship 2368433Authorship 2369384Authorship 2369901Authorship 2370571Authorship 2370824Authorship 23709610Authorship 2371901Authorship 2373661Authorship 2375205Authorship 2375325Authorship 2375942Authorship 2379493Authorship 2381281Authorship 2381462Authorship 2383693Authorship 2383771Authorship 2384304Authorship 2384422Authorship 2390872Authorship 2393201Authorship 2396033Authorship 2398383Authorship 2406572Authorship 24084812Authorship 2420275Authorship 2420492Authorship 2421247Authorship 2425325Authorship 2425511Authorship 24261926Authorship 2431483Authorship 2435305Authorship 2435529Authorship 2436412Authorship 2445782Authorship 2450493Authorship 2458396Authorship 2458854Authorship 2477421Authorship 2477675Authorship 2484183Authorship 249049Authorship 2500104Authorship 2520523Authorship 2526022Authorship 2528683Authorship 2532816Authorship 2540215Authorship 25455824Authorship 2546111Authorship 2546394Authorship 2549049Authorship 2551042Authorship 2556304Authorship 2558425Authorship 2558604Authorship 2563256Authorship 2569486Authorship 2578859Authorship 25856321Authorship 2588006Authorship 2590995Authorship 25962414Authorship 2603139Authorship 2607634Authorship 2610745Authorship 2622228Authorship 2623166Authorship 2625324Authorship 26262021316576Luke DR, Vadiei K, Lopez-Berestein GNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal AssociationRole of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 1992; 7(1):1-7.Nephrol Dial Transplant1992-01-01T00:00:001992Role of vascular congestion in cisplatin-induced acute renal failure in the rat.1759826Wasan KM, Vadiei K, Luke DR, Keyhani A, White RA, McQueen TJ, Mehta R, Lopez-Berestein GAntimicrobial agents and chemotherapyAntifungal activity of HWA-138 and amphotericin B in experimental systemic candidiasis. Antimicrob Agents Chemother. 1991 Oct; 35(10):2046-8.Antimicrob Agents Chemother1991-10-01T00:00:001991Antifungal activity of HWA-138 and amphotericin B in experimental systemic candidiasis.2205957Langston JD, Wasan KM, Lopez-Berestein G, Verani RR, Luke DRTransplantationEvaluation of amphotericin B-cyclosporine interaction in the rat. Transplantation. 1990 Sep; 50(3):506-10.Transplantation1990-09-01T00:00:001990Evaluation of amphotericin B-cyclosporine interaction in the rat.2295811Kilbourn R, Lopez-Berestein GJournal of immunology (Baltimore, Md. : 1950)Protease inhibitors block the macrophage-mediated inhibition of tumor cell mitochondrial respiration. J Immunol. 1990 Feb 01; 144(3):1042-5.J Immunol1990-02-01T00:00:001990Protease inhibitors block the macrophage-mediated inhibition of tumor cell mitochondrial respiration.2313133Wasan KM, Vadiei K, Lopez-Berestein G, Luke DRThe Journal of infectious diseasesPharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis. 1990 Mar; 161(3):562-6.J Infect Dis1990-03-01T00:00:001990Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats.2400807Howard OM, Talpaz M, Kantarjian H, Seong D, Wedrychowski A, Paslidis N, Hester J, Cork A, Turpin J, Lopez-Berestein GBloodInterferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Blood. 1990 Sep 15; 76(6):1117-30.Blood1990-09-15T00:00:001990Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.2470332Midez JA, Hopfer RL, Lopez-Berestein G, Mehta RTAntimicrobial agents and chemotherapyEffects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans. Antimicrob Agents Chemother. 1989 Feb; 33(2):152-5.Antimicrob Agents Chemother1989-02-01T00:00:001989Effects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans.2679695Lopez-Berestein GCurrent clinical topics in infectious diseasesLiposomes in infectious diseases: present and future. Curr Clin Top Infect Dis. 1989; 10:241-53.Curr Clin Top Infect Dis1989-01-01T00:00:001989Liposomes in infectious diseases: present and future.2842422Murray JL, Mehta K, Lopez-Berestein GJournal of leukocyte biologyInduction of adenosine deaminase and 5' nucleotidase activity in cultured human blood monocytes and monocytic leukemia (THP-1) cells by differentiating agents. J Leukoc Biol. 1988 Sep; 44(3):205-11.J Leukoc Biol1988-09-01T00:00:001988Induction of adenosine deaminase and 5' nucleotidase activity in cultured human blood monocytes and monocytic leukemia (THP-1) cells by differentiating agents.2867824Mehta K, Lopez-Berestein GCancer researchExpression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation. Cancer Res. 1986 Mar; 46(3):1388-94.Cancer Res1986-03-01T00:00:001986Expression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation.2871108Mehta K, Claringbold P, Lopez-Berestein GJournal of immunology (Baltimore, Md. : 1950)Amphotericin B inhibits the serum-induced expression of tissue transglutaminase in murine peritoneal macrophages. J Immunol. 1986 Jun 01; 136(11):4206-12.J Immunol1986-06-01T00:00:001986Amphotericin B inhibits the serum-induced expression of tissue transglutaminase in murine peritoneal macrophages.2883247Metha K, Turpin J, Lopez-Berestein GJournal of leukocyte biologyInduction of tissue transglutaminase in human peripheral blood monocytes by intracellular delivery of retinoids. J Leukoc Biol. 1987 Apr; 41(4):341-8.J Leukoc Biol1987-04-01T00:00:001987Induction of tissue transglutaminase in human peripheral blood monocytes by intracellular delivery of retinoids.2884257Mehta K, Claringbold P, Lopez-Berestein GJournal of immunology (Baltimore, Md. : 1950)Suppression of macrophage cytostatic activation by serum retinoids: a possible role for transglutaminase. J Immunol. 1987 Jun 01; 138(11):3902-6.J Immunol1987-06-01T00:00:001987Suppression of macrophage cytostatic activation by serum retinoids: a possible role for transglutaminase.3084457Turpin J, Hester JP, Hersh EM, Lopez-Berestein GJournal of clinical apheresisCentrifugal elutriation as a method for isolation of large numbers of functionally intact human peripheral blood monocytes. J Clin Apher. 1986; 3(2):111-8.J Clin Apher1986-01-01T00:00:001986Centrifugal elutriation as a method for isolation of large numbers of functionally intact human peripheral blood monocytes.3105625Lee J, Mehta K, Blick MB, Gutterman JU, Lopez-Berestein GBloodExpression of c-fos, c-myb, and c-myc in human monocytes: correlation with monocytic differentiation. Blood. 1987 May; 69(5):1542-5.Blood1987-05-01T00:00:001987Expression of c-fos, c-myb, and c-myc in human monocytes: correlation with monocytic differentiation.3342409Lautersztain J, Perez-Soler R, Turpin J, Khokhar AR, Siddik ZH, Schmidt K, Lopez-Berestein GCancer researchCellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes. Cancer Res. 1988 Mar 01; 48(5):1300-6.Cancer Res1988-03-01T00:00:001988Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes.3698012Klostergaard J, Foster WA, Hamilton DA, Turpin J, Lopez-Berestein GCancer researchEffector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: biochemical, functional, and serological characterization of cytotoxins produced by peripheral blood monocytes isolated by counterflow elutriation. Cancer Res. 1986 Jun; 46(6):2871-5.Cancer Res1986-06-01T00:00:001986Effector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: biochemical, functional, and serological characterization of cytotoxins produced by peripheral blood monocytes isolated by counterflow elutriation.3813512Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein GAntimicrobial agents and chemotherapyAntileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother. 1986 Dec; 30(6):847-51.Antimicrob Agents Chemother1986-12-01T00:00:001986Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.3925093Perez-Soler R, Lopez-Berestein G, Kasi LP, Cabanillas F, Jahns M, Glenn H, Hersh EM, Haynie TJournal of nuclear medicine : official publication, Society of Nuclear MedicineDistribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's disease. J Nucl Med. 1985 Jul; 26(7):743-9.J Nucl Med1985-07-01T00:00:001985Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's disease.3961167Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MARadiologyHepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology. 1986 May; 159(2):349-53.Radiology1986-05-01T00:00:001986Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B.4073873Mehta RT, Lopez-Berestein G, Hopfer RL, Mehta K, White RA, Juliano RLAntimicrobial agents and chemotherapyProphylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination. Antimicrob Agents Chemother. 1985 Oct; 28(4):511-3.Antimicrob Agents Chemother1985-10-01T00:00:001985Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination.6300230Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh EMJournal of immunology (Baltimore, Md. : 1950)The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol. 1983 Apr; 130(4):1500-2.J Immunol1983-04-01T00:00:001983The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues.6481163Kilbourn RG, Klostergaard J, Lopez-Berestein GJournal of immunology (Baltimore, Md. : 1950)Activated macrophages secrete a soluble factor that inhibits mitochondrial respiration of tumor cells. J Immunol. 1984 Nov; 133(5):2577-81.J Immunol1984-11-01T00:00:001984Activated macrophages secrete a soluble factor that inhibits mitochondrial respiration of tumor cells.6543694Lopez-Berestein G, Milas L, Hunter N, Mehta K, Hersh EM, Kurahara CG, Vandupas M, Eppstein DAClinical & experimental metastasisProphylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine. Clin Exp Metastasis. 1984 Apr-Jun; 2(2):127-37.Clin Exp Metastasis1984-04-01T00:00:001984Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-O-stearoyl-N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine.6679372Lopez-Berestein G, Reuben J, Hersh EM, Kilbourn R, Hester JP, Bielski M, Talpaz M, Mavligit GMTransfusionComparative functional analysis of lymphocytes and monocytes from plateletapheresis. Transfusion. 1983 May-Jun; 23(3):201-6.Transfusion1983-05-01T00:00:001983Comparative functional analysis of lymphocytes and monocytes from plateletapheresis.7704481Wasan KM, Lopez-Berestein GJournal of drug targetingThe interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J Drug Target. 1994; 2(5):373-80.J Drug Target1994-01-01T00:00:001994The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu.7811055Wasan KM, Grossie VB, Lopez-Berestein GAntimicrobial agents and chemotherapyConcentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother. 1994 Sep; 38(9):2224-6.Antimicrob Agents Chemother1994-09-01T00:00:001994Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion.8035564Wasan KM, Grossie VB, Lopez-Berestein GLaboratory animalsEffects of intralipid infusion on rat serum lipoproteins. Lab Anim. 1994 Apr; 28(2):138-42.Lab Anim1994-04-01T00:00:001994Effects of intralipid infusion on rat serum lipoproteins.8080218Wasan KM, Lopez-Berestein GAnnals of the New York Academy of SciencesModification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins. Ann N Y Acad Sci. 1994 Aug 15; 730:93-106.Ann N Y Acad Sci1994-08-15T00:00:001994Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins.8192447Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein GAntimicrobial agents and chemotherapyInfluence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother. 1994 Feb; 38(2):223-7.Antimicrob Agents Chemother1994-02-01T00:00:001994Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.8348074Engelhard D, Eldor A, Polacheck I, Hardan I, Ben-Yehuda D, Amselem S, Salkin IF, Lopez-Berestein G, Sacks T, Rachmilewitz EALeukemia & lymphomaDisseminated visceral fusariosis treated with amphotericin B-phospholipid complex. Leuk Lymphoma. 1993 Mar; 9(4-5):385-92.Leuk Lymphoma1993-03-01T00:00:001993Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex.8481912Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta KCancer researchInduction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res. 1993 May 01; 53(9):2100-4.Cancer Res1993-05-01T00:00:001993Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid.8515125Rios A, Rosenblum M, Crofoot G, Lenk RP, Hayman A, Lopez-Berestein GThe Journal of infectious diseasesPharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J Infect Dis. 1993 Jul; 168(1):253-4.J Infect Dis1993-07-01T00:00:001993Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection.8922813Wasan KM, Lopez-Berestein GClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaCharacteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis. 1996 Nov; 23(5):1126-38.Clin Infect Dis1996-11-01T00:00:001996Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients.9199202Tari AM, Arlinghaus R, Lopez-Berestein GBiochemical and biophysical research communicationsInhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem Biophys Res Commun. 1997 Jun 18; 235(2):383-8.Biochem Biophys Res Commun1997-06-18T00:00:001997Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.9333048Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, Klasterksy J, Sculier JP, DeValeriola D, Anaissie E, Lopez-Berestein G, Llanos-Cuentas A, Boyle A, Branch RAAntimicrobial agents and chemotherapyPharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother. 1997 Oct; 41(10):2201-8.Antimicrob Agents Chemother1997-10-01T00:00:001997Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.10498593Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating MBloodMolecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999 Oct 01; 94(7):2230-5.Blood1999-10-01T00:00:001999Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.10525110Guti?rrez-Puente Y, Tari AM, Stephens C, Rosenblum M, Guerra RT, Lopez-Berestein GThe Journal of pharmacology and experimental therapeuticsSafety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J Pharmacol Exp Ther. 1999 Nov; 291(2):865-9.J Pharmacol Exp Ther1999-11-01T00:00:001999Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2.10954918Diaz B, Lopez-Berestein GJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine ResearchA distinct element involved in lipopolysaccharide activation of the tumor necrosis factor-alpha promoter in monocytes. J Interferon Cytokine Res. 2000 Aug; 20(8):741-8.J Interferon Cytokine Res2000-08-01T00:00:002000A distinct element involved in lipopolysaccharide activation of the tumor necrosis factor-alpha promoter in monocytes.11133744Douer D, Estey E, Santillana S, Bennett JM, Lopez-Bernstein G, Boehm K, Williams TBloodTreatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood. 2001 Jan 01; 97(1):73-80.Blood2001-01-01T00:00:002001Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid.11175341Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AMOncogeneGrb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene. 2000 Dec 14; 19(54):6271-6.Oncogene2000-12-14T00:00:002000Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.11454891Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MCJournal of clinical oncology : official journal of the American Society of Clinical OncologyCationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.J Clin Oncol2001-07-15T00:00:002001Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.11706405Tari AM, Lopez-Berestein GSeminars in oncologyGRB2: a pivotal protein in signal transduction. Semin Oncol. 2001 Oct; 28(5 Suppl 16):142-7.Semin Oncol2001-10-01T00:00:002001GRB2: a pivotal protein in signal transduction.11948099Siwak DR, Tari AM, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer ResearchThe potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002. Clin Cancer Res. 2002 Apr; 8(4):955-6.Clin Cancer Res2002-04-01T00:00:002002The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.11964319Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff MBloodSynergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4.Blood2002-05-01T00:00:002002Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.12127961Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AMBiochemical and biophysical research communicationsDownregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun. 2002 Jul 26; 295(4):784-90.Biochem Biophys Res Commun2002-07-26T00:00:002002Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation.12138400Guti?rrez-Puente Y, Zapata-Benavides P, Tari AM, L?pez-Berestein GSeminars in oncologyBcl-2-related antisense therapy. Semin Oncol. 2002 Jun; 29(3 Suppl 11):71-6.Semin Oncol2002-06-01T00:00:002002Bcl-2-related antisense therapy.12467070Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PSCancerA multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61.Cancer2002-12-15T00:00:002002A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma.12935441Ozpolat B, Lopez-Berestein G, Adamson P, Fu CJ, Williams AHJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiquesPharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci. 2003 May-Aug; 6(2):292-301.J Pharm Pharm Sci2003-05-01T00:00:002003Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers.14738153Guti?rrez-Puente Y, Tari AM, Ford RJ, Tamez-Guerra R, Mercado-Hernandez R, Santoyo-Stephano M, Lopez-Berestein GLeukemia & lymphomaCellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk Lymphoma. 2003 Nov; 44(11):1979-85.Leuk Lymphoma2003-11-01T00:00:002003Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line.15142884Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, Mawuenyega KG, Tirado-Gomez M, Lopez-Berestein G, Chen XBloodComparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 2004 Sep 01; 104(5):1314-23.Blood2004-05-13T00:00:002004Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia.15908659Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005 May 20; 23(15):3495-501.J Clin Oncol2005-05-20T00:00:002005Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.16204013Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro JJournal of clinical oncology : official journal of the American Society of Clinical OncologyAntitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77.J Clin Oncol2005-10-03T00:00:002005Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.17259349Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S, Berestein GLMolecular cancer research : MCRProgrammed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 2007 Jan; 5(1):95-108.Mol Cancer Res2007-01-01T00:00:002007Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.17499461Cheema SK, Gobin AS, Rhea R, Lopez-Berestein G, Newman RA, Mathur ABInternational journal of pharmaceuticsSilk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int J Pharm. 2007 Aug 16; 341(1-2):221-9.Int J Pharm2007-04-03T00:00:002007Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.18336345Sanguino A, Lopez-Berestein G, Sood AKMini reviews in medicinal chemistryStrategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 2008 Mar; 8(3):248-55.Mini Rev Med Chem2008-03-01T00:00:002008Strategies for in vivo siRNA delivery in cancer.19110040Zhang HM, Chen SR, Cai YQ, Richardson TE, Driver LC, Lopez-Berestein G, Pan HLNeuroscienceSignaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord. Neuroscience. 2009 Feb 18; 158(4):1577-88.Neuroscience2008-12-07T00:00:002008Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord.19495686Mangala LS, Han HD, Lopez-Berestein G, Sood AKMethods in molecular biology (Clifton, N.J.)Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.Methods Mol Biol2009-01-01T00:00:002009Liposomal siRNA for ovarian cancer.19780895Cai YQ, Chen SR, Han HD, Sood AK, Lopez-Berestein G, Pan HLJournal of neurochemistryRole of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem. 2009 Nov; 111(4):1000-10.J Neurochem2009-09-23T00:00:002009Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats.19805003Shahzad MM, Lopez-Berestein G, Sood AKDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyNovel strategies for reversing platinum resistance. Drug Resist Updat. 2009 Dec; 12(6):148-52.Drug Resist Updat2009-10-04T00:00:002009Novel strategies for reversing platinum resistance.20059643Ozpolat B, Sood AK, Lopez-Berestein GJournal of internal medicineNanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53.J Intern Med2010-01-01T00:00:002010Nanomedicine based approaches for the delivery of siRNA in cancer.20389021Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SKThe Journal of clinical investigationAdrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May; 120(5):1515-23.J Clin Invest2010-04-12T00:00:002010Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.20708159Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AKCancer cellRegulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.Cancer Cell2010-08-09T00:00:002010Regulation of tumor angiogenesis by EZH2.20826776Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AKThe Journal of biological chemistryStress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov 12; 285(46):35462-70.J Biol Chem2010-09-08T00:00:002010Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.21160526Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AKNature reviews. CancerRNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67.Nat Rev Cancer2010-12-16T00:00:002010RNA interference in the clinic: challenges and future directions.21300758Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchFunctional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21.Clin Cancer Res2011-02-07T00:00:002011Functional roles of Src and Fgr in ovarian carcinoma.21358280Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AKCancer biology & therapyChitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45.Cancer Biol Ther2011-05-01T00:00:002011Chitosan hydrogel for localized gene silencing.21445297Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya RPloS oneEnhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.PLoS One2011-03-21T00:00:002011Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer.21512144Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer ResearchSilencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3716-26.Clin Cancer Res2011-04-21T00:00:002011Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.21647195Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GANature reviews. Clinical oncologyMicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011 Jun 07; 8(8):467-77.Nat Rev Clin Oncol2011-06-07T00:00:002011MicroRNAs in body fluids--the mix of hormones and biomarkers.22436627Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi RHuman pathologyClinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol. 2012 Oct; 43(10):1638-44.Hum Pathol2012-03-19T00:00:002012Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.22854961Zhou HY, Chen SR, Byun HS, Chen H, Li L, Han HD, Lopez-Berestein G, Sood AK, Pan HLThe Journal of biological chemistryN-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J Biol Chem. 2012 Sep 28; 287(40):33853-64.J Biol Chem2012-08-01T00:00:002012N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain.23200915Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AKGynecologic oncologyEpigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.Gynecol Oncol2012-11-28T00:00:002012Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.23386691Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer ResearchEnhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013 Apr 01; 19(7):1806-15.Clin Cancer Res2013-02-05T00:00:002013Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.23798432Jin Y, Qu S, Tesikova M, Wang L, Kristian A, M?landsmo GM, Kong H, Zhang T, Jer?nimo C, Teixeira MR, Yuca E, Tekedereli I, Gorgulu K, Alpay N, Sood AK, Lopez-Berestein G, Danielsen HE, Ozpolat B, Saatcioglu FProceedings of the National Academy of Sciences of the United States of AmericaMolecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):E2572-81.Proc Natl Acad Sci U S A2013-06-24T00:00:002013Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.23871637Masiero M, Sim?es FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Berestein G, Tuynman JB, Mortensen N, Li JL, Patient R, Sood AK, Banham AH, Harris AL, Buffa FMCancer cellA core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.Cancer Cell2013-07-18T00:00:002013A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.24079419Aslan B, Ozpolat B, Sood AK, Lopez-Berestein GJournal of drug targetingNanotechnology in cancer therapy. J Drug Target. 2013 Dec; 21(10):904-13.J Drug Target2013-09-30T00:00:002013Nanotechnology in cancer therapy.24613353Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan VCell reportsAutocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095.Cell Rep2014-03-06T00:00:002014Autocrine effects of tumor-derived complement.Authorship 2626551Authorship 2630604Authorship 263085Authorship 2632903Authorship 2633834Authorship 2633855Authorship 2642694Authorship 2644975Authorship 2648323Authorship 2652002Authorship 2658052Authorship 2672541Authorship 2677824Authorship 2681146Authorship 2686501Authorship 2686702Authorship 2688122Authorship 2688722Authorship 2692424Authorship 2698282Authorship 2699822Authorship 2704721Authorship 2706487Authorship 2711098Authorship 2716212Authorship 2718573Authorship 2722602Authorship 27238051640354Luke DR, Brunner LJ, Lopez-Berestein G, Yau JCJournal of pharmaceutical sciencesPharmacokinetics of cyclosporine in bone marrow transplantation: longitudinal characterization of drug in lipoprotein fractions. J Pharm Sci. 1992 Mar; 81(3):208-11.J Pharm Sci1992-03-01T00:00:001992Pharmacokinetics of cyclosporine in bone marrow transplantation: longitudinal characterization of drug in lipoprotein fractions.1687023Vadiei K, Lopez-Berestein G, Perez-Soler R, Luke DRDrug metabolism and disposition: the biological fate of chemicalsTissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Drug Metab Dispos. 1991 Nov-Dec; 19(6):1147-51.Drug Metab Dispos1991-11-01T00:00:001991Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine.1905388Turpin JA, Blick M, Hester JP, Lopez-Berestein GNatural immunity and cell growth regulationTumor necrosis factor and c-fos expression in human peripheral-blood monocytes: expression is dependent on stage of in vitro differentiation. Nat Immun Cell Growth Regul. 1991; 10(1):19-31.Nat Immun Cell Growth Regul1991-01-01T00:00:001991Tumor necrosis factor and c-fos expression in human peripheral-blood monocytes: expression is dependent on stage of in vitro differentiation.1908310Seong D, Sims S, Johnson E, Lyding J, Lopez A, Garovoy M, Talpaz M, Kantarjian H, Lopez-Berestein G, Reading CBritish journal of haematologyActivation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines. Br J Haematol. 1991 Jul; 78(3):359-67.Br J Haematol1991-07-01T00:00:001991Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines.2174873Wedrychowski A, Seong D, Paslidis N, Johnson E, Howard OM, Sims S, Talpaz M, Kantarjian H, Hester J, Turpin JThe Journal of biological chemistryCharacterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells. J Biol Chem. 1990 Dec 15; 265(35):21433-40.J Biol Chem1990-12-15T00:00:001990Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells.2578433Mehta RT, Mehta K, Lopez-Berestein G, Juliano RLInfection and immunityEffect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun. 1985 Feb; 47(2):429-33.Infect Immun1985-02-01T00:00:001985Effect of liposomal amphotericin B on murine macrophages and lymphocytes.3457624Anaissie E, Kantarjian H, Jones P, Barlogie B, Luna M, Lopez-Berestein G, Bodey GPCancerFusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer. 1986 Jun 01; 57(11):2141-5.Cancer1986-06-01T00:00:001986Fusarium. A newly recognized fungal pathogen in immunosuppressed patients.3860162Juliano RL, Lopez-Berestein G, Hopfer R, Mehta R, Mehta K, Mills KAnnals of the New York Academy of SciencesSelective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci. 1985; 446:390-402.Ann N Y Acad Sci1985-01-01T00:00:001985Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections.3894941Lopez-Berestein G, Kilbourn RNatural immunity and cell growth regulationMononuclear phagocyte system cytotoxins: a review. Nat Immun Cell Growth Regul. 1985; 4(2):78-89.Nat Immun Cell Growth Regul1985-01-01T00:00:001985Mononuclear phagocyte system cytotoxins: a review.4049293Kalter S, Lopez-Berestein GTexas medicineAcquired immune deficiency syndrome in a patient with prior sarcoidosis: case report with monocyte function studies. Tex Med. 1985 Sep; 81(9):44-6.Tex Med1985-09-01T00:00:001985Acquired immune deficiency syndrome in a patient with prior sarcoidosis: case report with monocyte function studies.6735607Kasi LP, Lopez-Berestein G, Mehta K, Rosenblum M, Glenn HJ, Haynie TP, Mavligit G, Hersh EMInternational journal of nuclear medicine and biologyDistribution and pharmacology of intravenous 99mTc-labeled multilamellar liposomes in rats and mice. Int J Nucl Med Biol. 1984; 11(1):35-7.Int J Nucl Med Biol1984-01-01T00:00:001984Distribution and pharmacology of intravenous 99mTc-labeled multilamellar liposomes in rats and mice.8907275Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berestein GLeukemia & lymphomaLiposomal delivery of oligodeoxynucleotides. Leuk Lymphoma. 1996 Mar; 21(1-2):93-7.Leuk Lymphoma1996-03-01T00:00:001996Liposomal delivery of oligodeoxynucleotides.9342185Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F, Ford RJCell growth & differentiation : the molecular biology journal of the American Association for Cancer ResearchRetinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ. 1997 Oct; 8(10):1071-82.Cell Growth Differ1997-10-01T00:00:001997Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas.10738260Tari AM, Lopez-Berestein GInternational journal of cancerSerum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively. Int J Cancer. 2000 Apr 15; 86(2):295-7.Int J Cancer2000-04-15T00:00:002000Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively.11501968Ozpolat B, Lopez-Berestein G, Mehta KJournal of biological regulators and homeostatic agentsATRA(ouble) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents. 2001 Apr-Jun; 15(2):107-22.J Biol Regul Homeost Agents2001-04-01T00:00:002001ATRA(ouble) in the treatment of acute promyelocytic leukemia.12753730Ng AW, Wasan KM, Lopez-Berestein GJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiquesDevelopment of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci. 2003 Jan-Apr; 6(1):67-83.J Pharm Pharm Sci2003-01-01T00:00:002003Development of liposomal polyene antibiotics: an historical perspective.16840198Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey ELeukemia & lymphomaSingle-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006 Jun; 47(6):1062-8.Leuk Lymphoma2006-06-01T00:00:002006Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.17106249Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AKCancer biology & therapyIntraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.Cancer Biol Ther2006-12-30T00:00:002006Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.17507797Ozpolat B, Akar U, Mehta K, Lopez-Berestein GAutophagyPKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy. 2007 Sep-Oct; 3(5):480-3.Autophagy2007-04-27T00:00:002007PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells.18413840Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta KClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2476-83.Clin Cancer Res2008-04-15T00:00:002008Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.19092150Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AKThe New England journal of medicineDicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.N Engl J Med2008-12-18T00:00:002008Dicer, Drosha, and outcomes in patients with ovarian cancer.20423989Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun BMolecular cancer therapeuticsTargeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7.Mol Cancer Ther2010-04-27T00:00:002010Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model.20708153Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RCCancer cellSIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010 Aug 09; 18(2):109-21.Cancer Cell2010-08-09T00:00:002010SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.21795478Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AKCancer researchBiological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9.Cancer Res2011-07-27T00:00:002011Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.22187436Li L, Cao XH, Chen SR, Han HD, Lopez-Berestein G, Sood AK, Pan HLThe Journal of biological chemistryUp-regulation of Cav?3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain. J Biol Chem. 2012 Feb 17; 287(8):6002-13.J Biol Chem2011-12-20T00:00:002011Up-regulation of Cav?3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain.22911754Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat BPloS oneTargeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171.PLoS One2012-07-20T00:00:002012Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.24384374Ozpolat B, Sood AK, Lopez-Berestein GAdvanced drug delivery reviewsLiposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6.Adv Drug Deliv Rev2013-12-30T00:00:002013Liposomal siRNA nanocarriers for cancer therapy.24743243Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, Previs RA, Han HD, Bottsford-Miller J, Zand B, Kang Y, Pecot CV, Nick AM, Wu SY, Lee JS, Sehgal V, Ram P, Liu J, Tucker SL, Lopez-Berestein G, Baggerly KA, Coleman RL, Sood AKCancer researchNotch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.Cancer Res2014-04-17T00:00:002014Notch3 pathway alterations in ovarian cancer.Authorship 2725323Authorship 2733206Authorship 2736013Authorship 2742093Authorship 2742262Authorship 27426318Authorship 2752964Authorship 2756371Authorship 2759191Authorship 2759863Authorship 2760044Authorship 2765643Authorship 2766524Authorship 27709251944727Luke DR, Wasan KM, Verani RR, Brunner LJ, Berens KL, Vadiei K, Lopez-Berestein GNephronAttenuation of amphotericin-B nephrotoxicity in the candidiasis rat model. Nephron. 1991; 59(1):139-44.Nephron1991-01-01T00:00:001991Attenuation of amphotericin-B nephrotoxicity in the candidiasis rat model.6470530Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RLThe Journal of infectious diseasesLiposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis. 1984 Aug; 150(2):278-83.J Infect Dis1984-08-01T00:00:001984Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice.8027667Newell CL, Deisseroth AB, Lopez-Berestein GJournal of leukocyte biologyInteraction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol. 1994 Jul; 56(1):27-35.J Leukoc Biol1994-07-01T00:00:001994Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene.8082414Mehta RT, McQueen TJ, Keyhani A, L?pez-Berestein GChemotherapyPhagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy. 1994 Jul-Aug; 40(4):256-64.Chemotherapy1994-07-01T00:00:001994Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B.9333054Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie EAntimicrobial agents and chemotherapyActivity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother. 1997 Oct; 41(10):2238-43.Antimicrob Agents Chemother1997-10-01T00:00:001997Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.9721088Hortobagyi GN, Hung MC, Lopez-Berestein GHuman gene therapyA Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther. 1998 Aug 10; 9(12):1775-98.Hum Gene Ther1998-08-10T00:00:001998A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.12149644Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein GOncogeneHer2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 2002 Aug 08; 21(34):5224-32.Oncogene2002-08-08T00:00:002002Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.16194896Ozpolat B, Mehta K, Lopez-Berestein GLeukemia & lymphomaRegulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells. Leuk Lymphoma. 2005 Oct; 46(10):1497-506.Leuk Lymphoma2005-10-01T00:00:002005Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.17374730Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez-Berestein GMolecular cancer research : MCRTissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res. 2007 Mar; 5(3):241-9.Mol Cancer Res2007-03-01T00:00:002007Tissue transglutaminase inhibits autophagy in pancreatic cancer cells.19408305Vivas-Mej?a PE, Ozpolat B, Chen X, Lopez-Berestein GInternational journal of cancerDownregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer. 2009 Jul 15; 125(2):264-75.Int J Cancer2009-07-15T00:00:002009Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.20538762Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchTargeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug 01; 16(15):3910-22.Clin Cancer Res2010-06-10T00:00:002010Targeted gene silencing using RGD-labeled chitosan nanoparticles.21531818Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AKClinical cancer research : an official journal of the American Association for Cancer ResearchDopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun 01; 17(11):3649-59.Clin Cancer Res2011-04-29T00:00:002011Dopamine blocks stress-mediated ovarian carcinoma growth.21754983Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJPloS oneIdentification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121.PLoS One2011-07-06T00:00:002011Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.21780419Lee JS, Rodr?guez-Luccioni HL, M?ndez J, Sood AK, Lpez-Berestein G, Rinaldi C, Torres-Lugo MJournal of nanoscience and nanotechnologyHyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol. 2011 May; 11(5):4153-7.J Nanosci Nanotechnol2011-05-01T00:00:002011Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum.24002999Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GACancer discoveryTherapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15.Cancer Discov2013-09-03T00:00:002013Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.2857744Mehta K, Lopez-Berestein G, Moore WT, Davies PJJournal of immunology (Baltimore, Md. : 1950)Interferon-gamma requires serum retinoids to promote the expression of tissue transglutaminase in cultured human blood monocytes. J Immunol. 1985 Apr; 134(4):2053-6.J Immunol1985-04-01T00:00:001985Interferon-gamma requires serum retinoids to promote the expression of tissue transglutaminase in cultured human blood monocytes.2818111Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, Gentry L, Mehta KArchives of internal medicineTreatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov; 149(11):2533-6.Arch Intern Med1989-11-01T00:00:001989Treatment of systemic fungal infections with liposomal amphotericin B.3613794Weber RS, Lopez-Berestein GThe LaryngoscopeTreatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope. 1987 Aug; 97(8 Pt 1):937-41.Laryngoscope1987-08-01T00:00:001987Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B.22812534Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RKBreast cancer research : BCRTargeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012 Jul 19; 14(4):R108.Breast Cancer Res2012-07-19T00:00:002012Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.24619206Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AKNature communications2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.Nat Commun2014-03-12T00:00:0020142'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.24703838Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AKCell reportsAntagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.Cell Rep2014-04-03T00:00:002014Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.24755199Gharpure KM, Chu KS, Bowerman CJ, Miyake T, Pradeep S, Mangala SL, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft JC, Napier ME, Lopez-Berestein G, DeSimone JM, Sood AKMolecular cancer therapeuticsMetronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.Mol Cancer Ther2014-04-22T00:00:002014Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.25193509Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein GMolecular cancer therapeuticsBisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2583-94.Mol Cancer Ther2014-09-05T00:00:002014Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.25230372Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang WThe Journal of pathologyMiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015 Jan; 235(1):25-36.J Pathol2014-11-06T00:00:002014MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.25277212Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SCNature communicationsCalcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.Nat Commun2014-10-03T00:00:002014Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.25281617Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AKMolecular cancer therapeuticsTherapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85.Mol Cancer Ther2014-10-03T00:00:002014Therapeutic silencing of KRAS using systemically delivered siRNAs.25738355Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein GOncotargetAdrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 2015 Feb 28; 6(6):4266-73.Oncotarget2015-02-28T00:00:002015Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.10022814Tari AM, Hung MC, Li K, Lopez-Berestein GOncogeneGrowth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 1999 Feb 11; 18(6):1325-32.Oncogene1999-02-11T00:00:001999Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.74Professor54Instructor14Associate Professor26853146Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gaf? R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GAMolecular cellAllele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell. 2016 Feb 18; 61(4):520-534.Mol Cell2016-02-04T00:00:002016Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.18006843Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AKCancer researchTherapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007 Nov 15; 67(22):10976-83.Cancer Res2007-11-15T00:00:002007Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.18182619Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, Somcio RJ, Lin YG, Lim S, Fan F, Mangala LS, Arumugam T, Logsdon CD, Lopez-Berestein G, Sood AK, Ellis LMJournal of the National Cancer InstituteTherapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.J Natl Cancer Inst2008-01-08T00:00:002008Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.Authorship 3743643Authorship 3743651Authorship 37442119Authorship 37442232Authorship 37442717Authorship 3744288Authorship 3746295Authorship 3746321Authorship 3746337Authorship 3746348Authorship 37463512Authorship 37463824Authorship 3746409Authorship 37464155622581827Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JSCarcinogenesisFOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012 Oct; 33(10):1843-53.Carcinogenesis2012-05-10T00:00:002012FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.22776561Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AKCancer lettersBiological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9.Cancer Lett2012-07-07T00:00:002012Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma.22966490Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, B?nhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, B?chet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahov? M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronj? MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, D?az-Araya G, D?az-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farr? JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, F?s?s L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et alAutophagyGuidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.Autophagy2012-04-01T00:00:002012Guidelines for the use and interpretation of assays for monitoring autophagy.18060038Fern?ndez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein GThe Journal of clinical investigationAn anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007 Dec; 117(12):4044-54.J Clin Invest2007-12-01T00:00:002007An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.18188003Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, Bursch W, Camougrand N, Cebollero E, Cecconi F, Chen Y, Chin LS, Choi A, Chu CT, Chung J, Clarke PG, Clark RS, Clarke SG, Clav? C, Cleveland JL, Codogno P, Colombo MI, Coto-Montes A, Cregg JM, Cuervo AM, Debnath J, Demarchi F, Dennis PB, Dennis PA, Deretic V, Devenish RJ, Di Sano F, Dice JF, Difiglia M, Dinesh-Kumar S, Distelhorst CW, Djavaheri-Mergny M, Dorsey FC, Dr?ge W, Dron M, Dunn WA, Duszenko M, Eissa NT, Elazar Z, Esclatine A, Eskelinen EL, F?s?s L, Finley KD, Fuentes JM, Fueyo J, Fujisaki K, Galliot B, Gao FB, Gewirtz DA, Gibson SB, Gohla A, Goldberg AL, Gonzalez R, Gonz?lez-Est?vez C, Gorski S, Gottlieb RA, H?ussinger D, He YW, Heidenreich K, Hill JA, H?yer-Hansen M, Hu X, Huang WP, Iwasaki A, J??ttel? M, Jackson WT, Jiang X, Jin S, Johansen T, Jung JU, Kadowaki M, Kang C, Kelekar A, Kessel DH, Kiel JA, Kim HP, Kimchi A, Kinsella TJ, Kiselyov K, Kitamoto K, Knecht E, Komatsu M, Kominami E, Kondo S, Kov?cs AL, Kroemer G, Kuan CY, Kumar R, Kundu M, Landry J, Laporte M, Le W, Lei HY, Lenardo MJ, Levine B, Lieberman A, Lim KL, Lin FC, Liou W, Liu LF, Lopez-Berestein G, L?pez-Ot?n C, Lu B, Macleod KF, Malorni W, Martinet W, Matsuoka K, Mautner J, Meijer AJ, Mel?ndez A, Michels P, Miotto G, Mistiaen WP, Mizushima N, Mograbi B, Monastyrska I, Moore MN, Moreira PI, Moriyasu Y, Motyl T, M?nz C, Murphy LO, Naqvi NI, Neufeld TP, Nishino I, Nixon RA, Noda T, N?rnberg B, Ogawa M, Oleinick NL, Olsen LJ, Ozpolat B, Paglin S, Palmer GE, Papassideri I, Parkes M, Perlmutter DH, Perry G, Piacentini M, Pinkas-Kramarski R, Prescott M, Proikas-Cezanne T, Raben N, Rami A, Reggiori F, Rohrer B, Rubinsztein DC, Ryan KM, Sadoshima J, Sakagami H, Sakai Y, Sandri M, Sasakawa C, Sass M, Schneider C, Seglen PO, Seleverstov O, Settleman J, Shacka JJ, Shapiro IM, Sibirny A, Silva-Zacarin EC, Simon HU, Simone C, Simonsen A, Smith MA, Spanel-Borowski K, Srinivas V, Steeves M, Stenmark H, Stromhaug PE, Subauste CS, Sugimoto S, Sulzer D, Suzuki T, Swanson MS, Tabas I, Takeshita F, Talbot NJ, Tall?czy Z, Tanaka K, Tanaka K, Tanida I, Taylor GS, Taylor JP, Terman A, Tettamanti G, Thompson CB, Thumm M, Tolkovsky AM, Tooze SA, Truant R, Tumanovska LV, Uchiyama Y, Ueno T, Uzc?tegui NL, van der Klei I, Vaquero EC, Vellai T, Vogel MW, Wang HG, Webster P, Wiley JW, Xi Z, Xiao G, Yahalom J, Yang JM, Yap G, Yin XM, Yoshimori T, Yu L, Yue Z, Yuzaki M, Zabirnyk O, Zheng X, Zhu X, Deter RLAutophagyGuidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008 Feb; 4(2):151-75.Autophagy2007-11-21T00:00:002007Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes.17483313Fern?ndez A, Sanguino A, Peng Z, Crespo A, Ozturk E, Zhang X, Wang S, Bornmann W, Lopez-Berestein GCancer researchRational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res. 2007 May 01; 67(9):4028-33.Cancer Res2007-05-01T00:00:002007Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.18806828Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LMOncogeneTherapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008 Dec 04; 27(57):7192-200.Oncogene2008-09-22T00:00:002008Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.19416223Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AIAnnals of the New York Academy of SciencesRelaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.Ann N Y Acad Sci2009-04-01T00:00:002009Relaxin/RXFP1 signaling in prostate cancer progression.20028751Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein GClinical cancer research : an official journal of the American Association for Cancer Researchc-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.Clin Cancer Res2009-12-22T00:00:002009c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.20724376Walton BL, Leja M, Vickers KC, Estevez-Fernandez M, Sanguino A, Wang E, Clubb FJ, Morrisett J, Lopez-Berestein GVascular medicine (London, England)Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits. Vasc Med. 2010 Aug; 15(4):307-13.Vasc Med2010-08-01T00:00:002010Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits.20542785Alviar CL, Tellez A, Wallace-Bradley D, Lopez-Berestein G, Sanguino A, Schulz DG, Builes A, Ballantyne CM, Yang CY, Kaluza GL, Granada JFEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of CardiologyImpact of adventitial neovascularisation on atherosclerotic plaque composition and vascular remodelling in a porcine model of coronary atherosclerosis. EuroIntervention. 2010 Apr; 5(8):981-8.EuroIntervention2010-04-01T00:00:002010Impact of adventitial neovascularisation on atherosclerotic plaque composition and vascular remodelling in a porcine model of coronary atherosclerosis.22335738Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AKThe New England journal of medicineParaneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8.N Engl J Med2012-02-16T00:00:002012Paraneoplastic thrombocytosis in ovarian cancer.Authorship 841085Authorship 841621Authorship 841897Authorship 841928Authorship 842038Authorship 842193Authorship 842391Authorship 842800Authorship 844610Authorship 845610Authorship 845756Authorship 845919Authorship 845920Authorship 846584Authorship 846695Authorship 846933Authorship 847170Authorship 847432Authorship 848739Authorship 848744Authorship 848990Authorship 850243Authorship 850322Authorship 850456Authorship 850512Authorship 850870Authorship 851170Authorship 851290Authorship 852065Authorship 852363Authorship 852411Authorship 852555Authorship 852673Authorship 852698Authorship 852784Authorship 853183Authorship 853429Authorship 853781Authorship 854302Authorship 854951Authorship 855165Authorship 855539Authorship 855903Authorship 856531Authorship 856769Authorship 857243Authorship 857680Authorship 858389Authorship 858812Authorship 858861Authorship 858956Authorship 859208Authorship 859254Authorship 859563Authorship 859801Authorship 860957Authorship 861045Authorship 861387Authorship 862669Authorship 862884Authorship 863258Authorship 863299Authorship 863545Authorship 864627Authorship 865211Authorship 865895Authorship 866057Authorship 866259Authorship 866419Authorship 866507Authorship 866752Authorship 867037Authorship 867229Authorship 867413Authorship 867611Authorship 868044Authorship 868076HepatologyDifferentiation therapy for hepatocellular carcinoma. Hepatology. Differentiation therapy for hepatocellular carcinomaJournal of Clinical InvestigationErratum. Journal of Clinical Investigation. 123:5411.ErratumInternational Journal of PharmaceuticsIn vitro evaluation of liposomal cyclosporine. International Journal of Pharmaceutics. 57:133-138.In vitro evaluation of liposomal cyclosporineProtective effect of liposomal-amphotericin-B (L-AMPB) on murine macrophages and lymphocytes. Protective effect of liposomal-amphotericin-B (L-AMPB) on murine macrophages and lymphocytesHeterogeneity of the production of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) by human peripheral blood monocytes (HPBM); in vitro maturation determines production levels. Heterogeneity of the production of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) by human peripheral blood monocytes (HPBM); in vitro maturation determines production levelsCancer BulletinGene therapy. Cancer Bulletin. 45:139-145.Gene therapyCell ReportsLong Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports. 13:2395-2402.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering GlycolysisCancer CellSalt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic NicheMolecular CellCorrection to Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2 [Molecular Cell 61, 520-534, (2016)]. Molecular Cell. 61:640.Correction to Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2 [Molecular Cell 61, 520-534, (2016)]Journal of Nuclear MedicineDistribution, retention and pharmacology of liposomes in rats. Journal of Nuclear Medicine. 23.Distribution, retention and pharmacology of liposomes in ratsCancer BulletinAntisense oligonucleotides and carriers for gene therapy. Cancer Bulletin. 45:164-170.Antisense oligonucleotides and carriers for gene therapyInduction of autophagy by polyphenolic compounds in cancer. 237-261.Induction of autophagy by polyphenolic compounds in cancerNature CommunicationsA miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications. 7.A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancerFederation ProceedingsHuman monocyte cytotoxins. Federation Proceedings. 44.Human monocyte cytotoxinsClinical Cancer ResearchNanotechnology. Clinical Cancer Research. 21:3121-3130.NanotechnologyJournal of Liposome ResearchClinical development of liposomal platinum. Journal of Liposome Research. 1:437-449.Clinical development of liposomal platinumOncogeneFunctional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancerJournal of Clinical InvestigationErratum. Journal of Clinical Investigation. 123:4980.ErratumJournal of Liposome ResearchPharmacokinetics, tissue distribution, and safety of P-ethoxy oligonucleotides incorporated in liposomes. Journal of Liposome Research. 8:251-264.Pharmacokinetics, tissue distribution, and safety of P-ethoxy oligonucleotides incorporated in liposomesRNAi in Cancer Therapy. 271-307.RNAi in Cancer TherapyBloodPharmacokinetics of intravenous liposomal all-trans-retinoic acid (ATRA) compared to oral atra in healthy subjects. Blood. 96.Pharmacokinetics of intravenous liposomal all-trans-retinoic acid (ATRA) compared to oral atra in healthy subjectsCancer CellErythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 28:610-622.Erythropoietin Stimulates Tumor Growth via EphB4OncotargetReciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 7:20825-20839.Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2HepatologyYes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 63:159-172.Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinomaFASEB JournalMonocytîc differentiation signals by tetradecanoyl phorbol acetate and retinoic acid differ in production of tumor necrosis factor-atext. FASEB Journal. 10.Monocytîc differentiation signals by tetradecanoyl phorbol acetate and retinoic acid differ in production of tumor necrosis factor-atextCancer DiscoveryMiRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discovery. 6:235-246.MiRNA deregulation in cancer cells and the tumor microenvironmentOncotargetChitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 6:29161-29177.Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagyProfiling long noncoding RNA expression using custom-designed microarray. 33-41.Profiling long noncoding RNA expression using custom-designed microarrayCell ReportsRole of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports. 17:1621-1631.Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine CancersJournal of Liposome ResearchPharmacokinetics, tissue distribution, and toxicology of tretinoin incorporated in liposomes. Journal of Liposome Research. 4:689-700.Pharmacokinetics, tissue distribution, and toxicology of tretinoin incorporated in liposomesProteoimic analysis of all-trans-retinoic acid treated acute promyelocytic leukemia cells using mass spectrometry and amino acid specific stable isotope labeling. 293-294.Proteoimic analysis of all-trans-retinoic acid treated acute promyelocytic leukemia cells using mass spectrometry and amino acid specific stable isotope labelingJournal of Liposome ResearchFormulation and toxicity of liposomes containing rifampicin. Journal of Liposome Research. 3:275-301.Formulation and toxicity of liposomes containing rifampicinFederation ProceedingsIncreased superoxide anion production by liposome-encapsulated muramyl dipeptide primed human monocyte. Federation Proceedings. 41.Increased superoxide anion production by liposome-encapsulated muramyl dipeptide primed human monocyteDrugs of the FutureAR-121. Drugs of the Future. 19:724-730.AR-121Nature CommunicationsThe ZNF304-integrin axis protects against anoikis in cancer. Nature Communications. 6.The ZNF304-integrin axis protects against anoikis in cancerCancer CellIntegrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer [Cancer Cell 23 (2013) 186-199]. Cancer Cell. 23:705.Integrated analyses identify a master microrna regulatory network for the mesenchymal subtype in serous ovarian cancer [Cancer Cell 23 (2013) 186-199]Molecular Systems BiologyA genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Molecular Systems Biology. 11:1-17.A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpressionPLoS OneRegulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT ativation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS One. 10.Regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT ativation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosisNatureTP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 520:697-701.TP53 loss creates therapeutic vulnerability in colorectal cancerEBioMedicineEBioMedicine. 12:34-42.EBioMedicineOncogeneSustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene. Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesisDistribution of 99mTC-labeled multilamellar liposomes (MLV) in patients (pts) with Hodgkin disease (HD). Distribution of 99mTC-labeled multilamellar liposomes (MLV) in patients (pts) with Hodgkin disease (HD)Cancer CellCancer Cell. 29:874-888.Cancer CellAssessment of In vivo siRNA delivery in cancer mouse models. 189-197.Assessment of In vivo siRNA delivery in cancer mouse modelsInternational Journal of PharmaceuticsPharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine. International Journal of Pharmaceutics. 57:125-131.Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporineOncotargetTherapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 7:15093-15104.Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancerBiology of the CellPharmacokinetic and therapeutic consequences of liposomal drug delivery. Biology of the Cell. 47:39-45.Pharmacokinetic and therapeutic consequences of liposomal drug deliveryJournal of Clinical InvestigationFAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation. 126:1885-1896.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawalPharmacy InternationalNew lives for old drugs. Pharmacy International. 6:164-167.New lives for old drugsNature CommunicationsErratum. Nature Communications. 4.ErratumOncogeneAntiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4Cell MetabolismTargeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism. 24:685-700.Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell GrowthJournal of Liposome ResearchTherapeutic activity of liposomal amphotericin b in systemic mycoses. Journal of Liposome Research. 1:511-516.Therapeutic activity of liposomal amphotericin b in systemic mycosesJournal of Liposome ResearchOligonucleotide therapy for hematological malignancies. Journal of Liposome Research. 7:19-30.Oligonucleotide therapy for hematological malignanciesMolecular Therapy - Nucleic AcidsTherapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Molecular Therapy - Nucleic Acids. 2.Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancerBreast Cancer ResearchCorrection. Breast Cancer Research. 14.CorrectionClinical Cancer ResearchRac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. Clinical Cancer Research. 21:2127-2137.Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancerAutophagyErratum to. Autophagy. 12:443.Erratum toCancer BulletinProspects for liposomes as a novel drug delivery system. Cancer Bulletin. 37:203-206.Prospects for liposomes as a novel drug delivery systemCancer ResearchUbiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research. 76:7194-7207.Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cellsOncogeneGrb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancerMolecular Cancer TherapeuticsLinalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Molecular Cancer Therapeutics. 15:618-627.Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinomaJournal of Liposome ResearchEffects of liposomal amphotericin b on human peripheral blood monocytes and lymphocytes. Journal of Liposome Research. 1:81-92.Effects of liposomal amphotericin b on human peripheral blood monocytes and lymphocytesAmphotericin B (AmpB) inhibits the serum-induced expression of tissue transglutaminase (TGase) in mouse peritoneal macrophages. Amphotericin B (AmpB) inhibits the serum-induced expression of tissue transglutaminase (TGase) in mouse peritoneal macrophagesOncogeneErratum. Oncogene. 35:801.ErratumInduction of tissue transglutaminase (TGase) in human monocytoid cells (THP-1) during retinoid and phorbol ester-induced differentation. Induction of tissue transglutaminase (TGase) in human monocytoid cells (THP-1) during retinoid and phorbol ester-induced differentationJournal of Liposome ResearchTargeted liposomes in fungi. Journal of Liposome Research. 5:883-903.Targeted liposomes in fungiCancer Biology and TherapyStress and the spread of ovarian cancer in mice. Cancer Biology and Therapy. 5:898.Stress and the spread of ovarian cancer in miceClinical Cancer ResearchAdrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research. 22:1713-1724.Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancerOncogeneHypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progressionAdvanced Drug Delivery ReviewsPreclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews. Preclinical and clinical development of siRNA-based therapeuticsAntimicrobial Agents and ChemotherapyErratum. Antimicrobial Agents and Chemotherapy. 38:2230.ErratumTumor cytotoxicity of human peripheral blood monocytes activated by muramyl dipeptide analogues. Tumor cytotoxicity of human peripheral blood monocytes activated by muramyl dipeptide analoguesCell ReportsDirect Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports. 15:1493-1504.Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian CancerAmerican Family PhysicianLiposomal administration of amphotericin B reduces toxicity. American Family Physician. 44:228.Liposomal administration of amphotericin B reduces toxicityOncogeneTargeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3pJournal of the National Cancer InstituteRole of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute. 108.Role of Increased n-acetylaspartate Levels in Cancer23052253Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann MClinical cancer research : an official journal of the American Association for Cancer ResearchHighly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.Clin Cancer Res2012-10-10T00:00:002012Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.8192464Gilbert BE, Wyde PR, Lopez-Berestein G, Wilson SZAntimicrobial agents and chemotherapyAerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother. 1994 Feb; 38(2):356-9.Antimicrob Agents Chemother1994-02-01T00:00:001994Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.16615096Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LHCancerBiologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006 Jun 01; 106(11):2437-44.Cancer2006-06-01T00:00:002006Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.17912453Tari AM, Guti?rrez-Puente Y, Monaco G, Stephens C, Sun T, Rosenblum M, Belmont J, Arlinghaus R, Lopez-Berestein GInternational journal of oncologyLiposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int J Oncol. 2007 Nov; 31(5):1243-50.Int J Oncol2007-11-01T00:00:002007Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts.20861284Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AIEndocrine-related cancerSuppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.Endocr Relat Cancer2010-10-29T00:00:002010Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis.D000666Chemicals & Drugs932880.882251Amphotericin BD034741Chemicals & Drugs77822160.625392RNA, Small InterferingD010051Disorders61946210.31574Ovarian NeoplasmsD014212Chemicals & Drugs2186230.798071TretinoinD008081Chemicals & Drugs2416830.830598LiposomesAuthorship 8992395Authorship 8997705Authorship 9009095Authorship 9014292Authorship 903454319437708Werner JH, Monta?o GA, Garcia AL, Zurek NA, Akhadov EA, Lopez GP, Shreve APLangmuir : the ACS journal of surfaces and colloidsFormation and dynamics of supported phospholipid membranes on a periodic nanotextured substrate. Langmuir. 2009 Mar 03; 25(5):2986-93.Langmuir2009-03-03T00:00:002009Formation and dynamics of supported phospholipid membranes on a periodic nanotextured substrate.20586429Wang Y, Tang Y, Zhou Z, Ji E, Lopez GP, Chi EY, Schanze KS, Whitten DGLangmuir : the ACS journal of surfaces and colloidsMembrane perturbation activity of cationic phenylene ethynylene oligomers and polymers: selectivity against model bacterial and mammalian membranes. Langmuir. 2010 Aug 03; 26(15):12509-14.Langmuir2010-08-03T00:00:002010Membrane perturbation activity of cationic phenylene ethynylene oligomers and polymers: selectivity against model bacterial and mammalian membranes.21740017Wang Y, Jones EM, Tang Y, Ji E, Lopez GP, Chi EY, Schanze KS, Whitten DGLangmuir : the ACS journal of surfaces and colloidsEffect of polymer chain length on membrane perturbation activity of cationic phenylene ethynylene oligomers and polymers. Langmuir. 2011 Sep 06; 27(17):10770-5.Langmuir2011-08-02T00:00:002011Effect of polymer chain length on membrane perturbation activity of cationic phenylene ethynylene oligomers and polymers.23024461Harris JM, Lopez GP, Reichert WMSensors and actuators. B, ChemicalSilica-dispersed glucose oxidase for glucose sensing: in vitro testing in serum and blood and the effect of condensation pH. Sens Actuators B Chem. 2012 Nov; 174:373-379.Sens Actuators B Chem2012-11-01T00:00:002012Silica-dispersed glucose oxidase for glucose sensing: in vitro testing in serum and blood and the effect of condensation pH.23911187Harris JM, Reyes C, Lopez GPJournal of diabetes science and technologyCommon causes of glucose oxidase instability in in vivo biosensing: a brief review. J Diabetes Sci Technol. 2013 Jul 01; 7(4):1030-8.J Diabetes Sci Technol2013-07-01T00:00:002013Common causes of glucose oxidase instability in in vivo biosensing: a brief review.21806944Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LMGastroenterologyIdentification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37.Gastroenterology2011-07-30T00:00:002011Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.18974154Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, Lopez-Berestein G, Sood AK, Bar-Eli MCancer researchTargeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008 Nov 01; 68(21):9078-86.Cancer Res2008-11-01T00:00:002008Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.21957230Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AKJournal of the National Cancer InstituteSilencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.J Natl Cancer Inst2011-09-28T00:00:002011Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.18314475Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AKJournal of the National Cancer InstituteEffect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 05; 100(5):359-72.J Natl Cancer Inst2008-02-26T00:00:002008Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.23360994Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AKNature communicationsSrc activation by ?-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403.Nat Commun2013-01-01T00:00:002013Src activation by ?-adrenoreceptors is a key switch for tumour metastasis.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1InstructorInstructor24799285Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath DMolecular systems biologyMetabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014 May 05; 10:728.Mol Syst Biol2014-05-05T00:00:002014Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.